Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation [1]

Leukemia

Volumn 17, Issue 2, 2003, Pages 458-460

  Vandenberghe, P ^a,b   Boeckx, N ^a   Ronsyn, E ^b   Decorte, R ^a   Verhoef, G ^c   Hagemeijer, A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b KU Leuven and University Hospitals Leuven and Leuven Cancer Institute   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DQB1 ANTIGEN; IMATINIB; MITOXANTRONE; PROTEIN TYROSINE KINASE INHIBITOR; THYMOCYTE ANTIBODY; TOPOTECAN;

ADULT; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DONOR; DRUG DESIGN; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FACE EDEMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; MONOCYTOSIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT CONTRAINDICATION;

EID: 0344520473     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402811     Document Type: Letter

References (8)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
2. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
3. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
4. Olavarria E, Craddock C, Dazzi F, Marin D, Marktel S, Apperley JF, Goldman JM. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861-3862.
5. Wassmann B, Klein SA, Scheuring U, Pfeifer H, Martin H, Gschaidmeier H, Hoelzer D, Ottmann OG. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 721-724.
6. Baron F, Frere P, Fillet G, Beguin Y. Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. Haematologica 2001; 86: 993-994.
7. Wang HW, Cheng FD, Cuenca AG, Bhalla K, Sotomayor EM. STI-571, a selective tyrosine kinase inhibitor, significantly enhances antigen presentation by bone marrow derived APCs: implications for immunotherapy of tumors derived from antigen presenting cells. Blood 2001; 98: 16a.
8. Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL, Hokland P. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67: 302-308.